Acute kidney injury: Not just acute renal failure anymore?

Critical Care Nurse

Volumn 31, Issue 1, 2011, Pages 37-50

  Dirkes, Susan ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; HAVCR1 PROTEIN, HUMAN; INTERLEUKIN 18; LCN2 PROTEIN, HUMAN; LIPOCALIN; MEMBRANE PROTEIN; ONCOPROTEIN; VIRUS RECEPTOR;

ACUTE KIDNEY FAILURE; ARTICLE; BLOOD; CLASSIFICATION; CRITICAL ILLNESS; HOSPITALIZATION; HUMAN; NOMENCLATURE;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; BIOLOGICAL MARKERS; CRITICAL ILLNESS; HUMANS; INTERLEUKIN-18; LIPOCALINS; MEMBRANE GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTORS, VIRUS; SEVERITY OF ILLNESS INDEX; TERMINOLOGY AS TOPIC;

EID: 79960622785     PISSN: 02795442     EISSN: None     Source Type: Journal    
DOI: 10.4037/ccn2011946     Document Type: Article

References (149)

1. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31. http://ccforum.com/content/11/2/R31. Accessed November 3, 2010.
2. Ostermann M, Chang R, Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med. 2007;35(8):1837-1842.
3. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. JAMA. 1996;275:1489-1494.
4. Venkataraman R. Can we prevent acute kidney injury? Crit Care Med. 2008;36(4 suppl): S166-S171.
5. Bellomo R, Kellum J, Ronco C. Acute renal failure: time for consensus. Intensive Care Med. 2001;27(11):1685-1688.
6. Bellomo R, Ronco C, Kellum JA, et al; Acute Dialysis Quality Initiative workgroup. Acute renal failure: definition, outcome measures, animal model, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204-R212.
7. Uchino S, Kellum JA, Bellomo R, et al; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813-818.
8. Hoste EA, Kellum JA. RIFLE criteria provide a robust assessment of kidney dysfunction and correlate with hospital mortality. Crit Care Med. 2006;12:531-537.
9. deMendonaca A, Vincent JL, Suter PM, et al. Acute renal failure in the ICU: risk factors and outcome evaluated by SOFA score. Intensive Care Med. 2000;26(7):915-921.
10. Kellum JA, Angus DC. Patients are dying of acute renal failure. Crit Care Med. 2002;30(9):2156-2157.
11. Hoste EA, Clemont G, Kersten A, et al. RIFLE criteria for acute kidney injury is associated with hospital mortality in critical ill patients: a cohort analysis. Crit Care. 2006; 10(3):R73. http://ccforum.com/content/10/3/R73. Published May 12, 2006. Accessed November 3, 2010.
12. Kellum JA, Levin N. Bouman C, et al. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care. 2002; 8:509-514.
13. Dennen P, Douglas I, Anderson R. Acute kidney injury in the intensive care unit: an update and primer for the intensivist. Crit Care Med. 2010;38(1):261-275.
14. Hoste EM, Lameire NH, Vanholder RC, et al. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol. 2003;14:1022-1030.
15. Kellum JA. Acute kidney injury. Crit Care Med. 2008;36(4 suppl):S141-S145.
16. Abosaif NY, Tolba YA, Heap M, et al. The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity and predictability. Am J Kidney Dis. 2005;46:1038-1048.
17. Uchino S, Bellomo R, Goldsmith D. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med. 2006;34:1913-1917.
18. Maccariello E, Soares M, Valente C, et al. RIFLE classification in patients with acute kidney injury in need of renal replacement. Intensive Care Med. 2007;33(4):597-605.
19. Ali T, Khan I, Simpson W, et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol. 2007;18(4):1292-1298.
20. Bagshaw SM, Gibney RT. Conventional markers of kidney function. Crit Care Med. 2008;36(4 suppl):S152-S158.
21. Ronco C, Bagshaw SM. Kidney function tests and urinalysis in acute renal failure. In: Critical Care Nephrology. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2009:251-259.
22. Star RA. Treatment of acute renal failure. Kidney Int. 1998;54:1817-1831.
23. Stevens LA, Levy AS. Measurement of kidney function. Med Clin North Am. 2005;89: 457-473.
24. Slotman GJ, Fisher CJ Jr, Bone RC, Clemmer TP, Metz CA. Detrimental effects of highdose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock. The Methylprednisolone Severe Sepsis Study Group. Crit Care Med. 1993;21(2):191-195.
25. Kasiske BL, Keane WF. Laboratory assessment of renal disease: clearance, urinalysis and renal biopsy. In: Brenner BM, ed. Brenner and Rector's The Kidney. Vol 1. 6th ed. Philadelphia, PA:WB Saunders Co; 2000: 1129-1170.
26. Bankir L, Trih-Trang-Tan MM. Urea and the kidney. In: Brenner BM, ed. Brenner and Rector's The Kidney. Vol 1. 6th ed. Philadelphia, PA: WB Saunders Co; 2000:637-679.
27. Zarich S, Fang LS, Deamond JR. Fractional excretion of sodium: exceptions to its diagnostic value. Arch Intern Med. 1985;45(1): 108-112.
28. Pru C, Kjellstrand CM. The FENa test is of no prognostic value in acute renal failure. Nephron. 1984;36(1):20-23.
29. Carvounis CP, Nisar S, Guro-Razuman S. Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int. 2002;62:2223-2229.
30. Kaplan AA, Kohn OF. Fractional excretion of urea as a guide to renal dysfunction. Am J Nephrol. 1992;12:49-54.
31. Langenberg C,Wan L, Bagshaw SM, et al. Urinary biochemistry in experimental septic acute renal failure. Nephrol Dial Transplant. 2006;21:3389-3397.
32. Mehta RL, Pascual MT, Soroko S, et al. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int. 2004;66:1613-1617.
33. Block CA, Schoolwerth AC. The epidemiology and outcome of acute renal failure and the impact on chronic kidney disease. Semin Dial. 2006;19:450-454.
34. Bellomo R. Defining, quantifying and classifying acute renal failure. Crit Care Clin. 2005; 21:223-237.
35. Fischer MJ, Brimhall BB, Lezotte DC, et al. Uncomplicated acute renal failure and hospital resource utilization: a retrospective multicenter analysis. Am J Kidney Dis. 2005;46:1049-1057.
36. Hamel MB, Phillips RS, Davis RB, et al. Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults: SUPPORT investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med. 1997; 127(3):195-202.
37. Parikh CR, Devarjan P. New biomarkers for acute kidney injury. Crit Care Med. 2008; 36(4)(suppl):S159-S165.
38. Luyckx VA, Bonaventra JC. Biomarkers in acute kidney. In: Ronco C, Bellomo R, Kellum J, eds. Critical Care Nephrology. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2009: 259-263.
39. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14: 2534-2543.
40. Melnikov VY, Ecder T, Fantuzzi G, et al. Impaired IL-18 processing protects caspase 1-deficient mice from ischemic acute renal failure. J Clin Invest. 2001;107:1145-1152.
41. Parikh CR, Jani A. Melnikov VY, et al. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis. 2004;43:405-414.
42. Parikh CR, Abraham E, Ancukiewicz M, et al. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol. 2005;16:3046-3052.
43. Mori K, Lee HT Rapoport D, et al. Endocytic delivery of lipocalin-siderophore- iron complex rescues the kidney from ischemiareperfusion injury. J Clin Invest. 2005;115: 610-621.
44. Mishra J, Mori K, Ma Q, et al. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol. 2004;24:307-315.
45. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365:1231-1238.
46. Kümpers P, Hafer C, Lukasz A, et al. Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in patients with acute kidney injury. Crit Care. 2010;14(1):R9.
47. Mishra J, Ma Q, Kelly C, et al. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol. 2006;21(6):856-863.
48. Ichimura T, Bonventre JV, Bailly V, et al. Kidney injury molecule-1 (KIM-1) a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is upregulated in renal cells after injury. J Biol Chem. 1998;273(7):4135-4142.
49. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62(1):237-244.
50. HanWK,Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury [published correction appears in Kidney Int. 2009;76(3):348-349]. Kidney Int. 2008;73(7):863-869.
51. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med. 1998;104(4):343-348.
52. Abel RM, Beck CH Jr, Abbott WM, Ryan JA Jr, Barnett GO, Fischer JE. Improved survival from acute renal failure after treatment with essential L-amino acids and glucose: results of a prospective, double-blind study. N Engl J Med. 1973;288(14): 695-699.
53. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331(21):1416-1420.
54. Better OS, Rubinstein I. Management of shock and acute renal failure in casualties suffering from the crush syndrome. Ren Fail. 1997;19(5):647-653.
55. Bagshaw SM, Bellomo R, Kellum JA. Oliguria, volume overload and loop diuretics. Crit Care Med. 2008;36(4 suppl):S172-S178.
56. Van Biesen W, Yegenaga I, Vanholder R, et al. Relationship between fluid status and its management on acute renal failure (ARF) in intensive care unit (ICU) patients with sepsis: a prospective analysis. J Nephrol. 2005; 8:54-60.
57. Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354:2564-2575.
58. Sakr Y, Vincent JL, Reinhart K, et al. High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest. 2005;128:3098-3108.
59. Simmons RS, Berdine GG Seidenfeld JJ, et al. Fluid balance and the adult respiratory distress syndrome. Am Rev Respir Dis. 1987;135: 924-929.
60. Brandstrup B, Tønnesen H, Bier-Holgersen R, et al; Danish Study Group on Perioperative Fluid Therapy. Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg. 2003;238(5):641-648.
61. Nisanevich V, Felsenstein I, Almogy G, Weissman C, Einav S, Matot I. Effect of intraoperative fluid management on outcome after intraabdominal surgery. Anesthesiology. 2005;103(1):25-32.
62. Bone RC, Balk RA, Cerra FB, et al.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644-1655.
63. Rivers E, Mguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-1377.
64. Cotton BA, Guy JS, Morris JA, Abrumad NN. The cellular, metabolic, and systemic consequences of aggressive fluid resuscitation strategies. Shock. 2006;26:115-121.
65. Gladwin MT, Raat NJ, Shiva S, et al. Nitrite as a vascular endocrine nitric oxide reservoir that contributes to hypoxic signaling, cytoprotection, and vasodilation. Am J Physiol. 2006;291:H2026-H2035.
66. Maertz L, Kaplan L. Abdominal compartment syndrome. Crit Care Med. 2008;36(4 suppl):S212-S215.
67. Sugrue M. Abdominal compartment syndrome. Curr Opin Crit Care. 2005;11:333-338.
68. Lambert DM, Marceau S, Forse RA. Intraabdominal pressure in the morbidly obese. Obes Surg. 2005;15(9):1225-1232.
69. Cheatham M, White MW, Sagraves SG, et al. Abdominal perfusion pressure: a superior parameter in the assessment of intraabdominal hypertension. J Trauma. 2000; 45:621-626.
70. Balogh Z, Mckinley BA, Cocanour C, et al. Patientswith impending abdominal compartment syndrome do not respond to early volume loading. Am J Surg. 2003;186:602-607.
71. LeBlanc M, Kellum JA, Gibney N, et al. Risk factors for acute renal failure: inherent and modifiable risks. Curr Opin Crit Care. 2005; 11:533-556.
72. Santos WJ, Zanetta DM, Pires AC, et al. Patients with ischaemic, mixed and nephrotoxic acute tubular necrosis in the intensive care unit-a homogeneous population? Crit Care. 2006;10:R68.
73. Pannu N, Nadim M. An overview of druginduced acute kidney injury. Crit Care Med. 2008;36(4 suppl):S216-S223.
74. Swan SK. Aminoglycoside toxicity. Semin Nephrol. 1997;17(1):27-33.
75. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43:1003-1012.
76. Olbricht CJ, Fink M, Gutjahr E. Alterations in lysosomal enzymes of the proximal tubule in gentamicin toxicity. Kidney Int. 1991;39: 639-646.
77. Paterson DL, Robson JM, Wagener MM. Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen Intern Med. 1998;13:735-739.
78. RybakMJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43:1549-1555.
79. Barza M, Ioannidis JP, Cappelleri JL, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996;312: 338-345.
80. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: ameta-analysis. Ann Intern Med. 1996;124:717-725.
81. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother. 1996;37:645-663.
82. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomized controlled trial. BMJ. 2001;322:579-582.
83. Harbath S, Pestotnik SL, Lloyd JF, et al. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med. 2001;111:528-534.
84. Sabra R, Zeinoun N, Sharaf LH, et al. Role of humoral mediators in and influence of a liposomal formulation on acute amphotericin B nephrotoxicity. Pharmacol Toxicol. 2001;88:168-175.
85. Burdmann E. Drug-induced acute renal failure. In: Ronco C, Bellomo R, Kellum JA, eds. Critical Care Nephrology. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2009:317-324.
86. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol. 1995;6:154-164.
87. Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int. 1991;40:302-308.
88. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis. 2006;42(suppl 1):S51-S57.
89. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990;25(4):679-687.
90. Hydayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166:2138-2144.
91. Barraclough K, Harris M. Montessori V, et al. An unusual case of acute kidney injury due to vancomycin: lessons learnt from reliance on eGFR. Nephrol Dial Transplant. 2007;22:2391-2394.
92. Chew DP, Astley C, Molloy D, et al. Morbidity, mortality and economic burden of renal impairment in cardiac intensive care. Intern Med J. 2007;36:185-192.
93. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95:13-19.
94. Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol. 2003; 181(6):1463-1471.
95. Lindsay J, Apple S, Pinnow EE, at al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv. 2003;59(3):338-343.
96. Al-Ghonaim M, Pannu N. Prevention and treatment of contrast-induced nephropathy. Tech Vasc Interv Radiol. 2006;9(2):42-49.
97. Lindsay J, Canos DA, Apple S, et al. Causes of acute renal dysfunction after percutaneous coronary intervention and comparison of late mortality rates with postprocedure rise of creatinine kinase-MB versus rise of serum creatinine. Am J Cardiol. 2004;94:786-789.
98. Mehran R., Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393-1399.
99. Barrett BJ, Carlisle EJ. Meta-analysis of the relative nephrotoxicity of high- and lowosmolality iodinated contrast media. Radiology. 1993;188:171-178.
100. McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006;98:27K-36K.
101. McCullough PA. Acute kidney injury with iodinated contrast. Crit Care Med. 2008; 36(4 suppl):S204-S211.
102. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003;349:1333-1340.
103. Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest. 1998;114(6): 1570-1574.
104. Briguori C, Airoldi F, D'Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventative strategies. Circulation. 2007;115:1211-1217.
105. Bagshaw SM, Delaney A, Jones D, et al. Diuretics in the management of acute kidney injury: a multinational survey. Contrib Nephrol. 2007;156:236-249.
106. Mehta RL, Pascual MT, Soroko S, et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288:2547-2553.
107. Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001;29:1526-1531.
108. Marik PE. Low-dose dopamine: a systematic review. Intensive Care Med. 2002;28:877-883.
109. Friedrich JO, Adhikari N, Herridge MS, et al. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005; 142:510-524.
110. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebocontrolled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 2000; 356(9248):2139-2143.
111. Halpennny M, Rushe C, Breen P, et al. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. Eur J Anaesthesiol. 2002;19:32-39.
112. Morelli A, Ricci Z, Bellomo R, et al. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebocontrolled pilot. Crit Care Med. 2005;33: 2451-2456.
113. Landoni G, Biondi-Zoccai GG, Tumlin JA, et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for renal failure: a meta-analysis of randomized clinical trials. N Engl J Med. 1997;336:828-834.
114. Ricksten SE, Swärd K. Atrial natriuretic peptide in acute renal failure. In: Ronco C, Bellomo R, Kellum JA, eds. Critical Care Nephrology. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2009:429-433.
115. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necroses: Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med. 1997;336(12):828-834.
116. Swärd K, Valsson F, Odencrants P, Samuelsson O, Ricksten SE. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial [published correction appears in Crit Care Med. 2006;34(6):1862]. Crit Care Med. 2004;32(6):1310-1315.
117. Singbartl K, Zarbock A. Antioxidants. In: Ronco C, Bellomo R, Kellum JA, eds. Critical Care Nephrology. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2009:435-438.
118. Pannu N, Manns B, Lee H, et al. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int. 2004;65: 1366-1374.
119. Hoffman U, Fischereder M, Kruger B, et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004;15:407-410.
120. Subramanian S, Kellum JA, Ronco C. Oliguria. In: Ronco C, Bellomo R, Kellum JA, eds. Critical Care Nephrology. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2009:341-345.
121. Ho KM, Sheridan DJ. Meta-analysis of furosemide to prevent or treat acute renal failure. BMJ. 2006;333(7565):420.
122. Aravandin N, Aravandin S, Reidel BJ, et al. Furosemide prevents apoptosis and associated gene expression in a rat model of surgical ischemic acute renal failure. Ren Fail. 2007;29:399-407.
123. Oppermann M, Hansen PB, Castrop H, et al. Vasodilatation of afferent arterioles and paradoxical increase of renal vascular resistance by furosemide in mice. Am J Physiol Renal Physiol. 2007;293:F279-F287.
124. Pedersen M, Vajda Z, Stodkilde-Jorgensen H, et al. Furosemide increases water content in renal tissue. Am J Physiol Renal Physiol. 2007;292:F1645-F1651.
125. Yuengsrigul A, Chin TW, Nussbaum E. Immunosuppressive and cytotoxic effects of furosemide on human peripheral blood mononuclear cells. Ann Allergy Asthma Immunol. 1999;83:559-566.
126. Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, Weisberg LS. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 1998;31(4): 674-680.
127. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiographyrelated renal tissue injury (the APART trial). Am J Cardiol. 2002;89:356-358.
128. Barr LF, Kolodner K. N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery. Crit Care Med. 2008;36(5):1427-1436.
129. Leypoldt J. Intermittent techniques for acute dialysis. In: Ronco C, Bellomo R, Kellum JA, eds. Critical Care Nephrology. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2009:1203-1206.
130. Palevsky P. Indication and timing of renal replacement therapy. Crit Care Med. 2008;36(4 suppl):S224-S228.
131. Gutch CF. Principles of hemodialysis. In: Gutch CF, Stoner MH, Corea AL. Review of Hemodialysis for Nurses and Dialysis Personnel. 6th ed. St Louis, MO: Mosby; 1999:35-47.
132. Ronco C, Cruz D, Bellomo R. Continuous renal replacement in critical illness. Contrib Nephrol. 2007;156:309-319.
133. Chater K, Kellum J. Continuous vs intermittent hemodialysis: which spin will my patient win? Crit Care. 2007;11:313-314.
134. Nissenson A, Rastogi A. Renal replacement therapy in the intensive care unit. In: Ronco C, Bellomo R, Kellum JA, eds. Critical Care Nephrology. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2009:1125-1128.
135. Conger JD. Does hemodialysis delay recovery from acute renal failure? Semin Dial. 1990;3:146-148.
136. Dworkin LD, Sun AM, Brenner, B. The renal circulations. In: Brenner BM, ed. Brenner and Rector's The Kidney. Vol 1. 6th ed. Philadelphia, PA: WB Saunders Co; 2000: 277-318.
137. Sung FL, Zhu TY, Au-Yeung KK, et al. Enhanced MCP-1 expression during ischemia/reperfusion injury is mediated by oxidative stress and NF-κB. Kidney Int. 2002;62:1160-1170.
138. Burne-Taney MJ, Rabb H. The role of adhesion molecules and T cells in ischemic renal injury. Curr Opin Nephrol Hypertens. 2003; 12:85-90.
139. Racusen L, Fivush B, Li Y, et al. Dissociation of tubular cell detachment and tubular cell death in clinical and experimental "acute tubular necroses." Lab Invest. 1991;64:54-56.
140. Cerda J, Ronco C. Modalities of continuous renal replacement therapy: technical and clinical considerations. Semin Dial. 2009; 22(2):114-122.
141. Vinsonneau C, Ridel C, Dhainaut JF. Indications for and contraindications to intermittent hemodialysis in critically ill patients. In: Ronco C, Bellomo R, Kellum JA, eds. Critical Care Nephrology. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2009:1239-1243.
142. Rodby R. The case of increased renal replacement therapy dosing in ICU patients with acute renal failure: re-examining the current evidence. NxStage Medical IncWeb site. http://www.nxstage.com/acute_renal_care/upload/Dr-Rodby-Whitepaper-2.pdf . Published 2007. Accessed November 8, 2010.
143. Ronco C, Cruz D, Bellomo R. Continuous renal replacement therapy in critical illness. Contrib Nephrol. 2007;156:309-319.
144. Rauf AA, Long KH, Gajic O, Anderson SS, Swaminathan L, Albright RC. Intermittent hemodialysis versus continuous renal replacement therapy for acute renal failure in the intensive care unit: an observational outcome analysis. J Intensive Care Med. 2008; 23(3):195-203.
145. Jack MJ, Ivancinova X, Gibney RT. Continuous renal replacement therapy improves renal recovery from acute renal failure. Can J Anaesth. 2005;52:327-332.
146. Swartz R, Messana JM, Orzol S, et al. Comparing continuous hemofiltration with hemodialysis in patients with severe acute renal failure. Am J Kidney Dis. 1999;34:424-432.
147. Uchino S, Bellomo R, Kellum JA, et al; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators Writing Committee. Patient and kidney survival by dialysis modality in critically ill patients with acute kidney injury. Int J Artif Organs. 2007;30(4):281-292.
148. Vinsonneau C, Camus C, Combes A, et al; Hemodiafe Study Group. Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple organ dysfunction syndrome: a multicentre randomised trial. Lancet. 2006;368(9533):379-385.
149. VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, O'Connor TZ, et al. Intensity of support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359(1):7-20.